Effect of Liraglutide on Blood Glucose Control in Subjects With Type 2 Diabetes

NCT00393718 · Completed

Last updated 2026-05-28

This clinical trial tested the effect of the medication liraglutide on blood sugar control in adults with type 2 diabetes over a 24-week period.

Status Completed The study has finished.

Phase Phase 3 Confirms effectiveness in a large group before approval.

Type Interventional (clinical trial)

Design Randomized, double-blind treatment study

Participants 400 people

Who can join Ages 20+ · all sexes

Timeline Started 2006-11 · est. completion 2008-05

Where 1 site · Japan

What this study is testing ClinicalTrials.gov NCT00393718 ↗

Description as written by the study sponsor.

This trial is conducted in Japan. The trial aims for comparison of the effect on glycaemic control of liraglutide, compared to sulfonylurea (SU treatment), as assessed by HbA1c after 24 and 52 weeks in subjects with type 2 diabetes. Trial has a randomisation period of 24 weeks followed by a 28 week extension period, in total 52 weeks.

Treatments tested

liraglutide Drug

0.9 mg/day. Injected s.c. (under the skin) once daily.
glibenclamide Drug

1.25-2.5 mg tablet. Given orally once or twice daily.
placebo Drug

liraglutide placebo. Injected s.c. (under the skin) once daily.
placebo Drug

glibenclamide placebo. Given orally once or twice daily.

Main thing measured	Glycosylated Haemoglobin A1c (HbA1c) After 24 Weeks of Treatment
Sponsor	Novo Nordisk A/S
Conditions studied	Diabetes, Diabetes Mellitus, Type 2
GLP-1 drugs	liraglutide

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT00393718 ↗